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Evolution of the Pseudomonas 
aeruginosa mutational resistome 
in an international Cystic Fibrosis 
clone
Carla López-Causapé1, Lea Mette Sommer2, Gabriel Cabot1, Rosa Rubio1, Alain A. Ocampo-
Sosa3, Helle Krogh Johansen2, Joan Figuerola4, Rafael Cantón5, Timothy J. Kidd 6,7, Soeren 
Molin2 & Antonio Oliver 1
Emergence of epidemic clones and antibiotic resistance development compromises the management of 
Pseudomonas aeruginosa cystic fibrosis (CF) chronic respiratory infections. Whole genome sequencing 
(WGS) was used to decipher the phylogeny, interpatient dissemination, WGS mutator genotypes 
(mutome) and resistome of a widespread clone (CC274), in isolates from two highly-distant countries, 
Australia and Spain, covering an 18-year period. The coexistence of two divergent CC274 clonal lineages 
was revealed, but without evident geographical barrier; phylogenetic reconstructions and mutational 
resistome demonstrated the interpatient transmission of mutators. The extraordinary capacity of P. 
aeruginosa to develop resistance was evidenced by the emergence of mutations in >100 genes related 
to antibiotic resistance during the evolution of CC274, catalyzed by mutator phenotypes. While the 
presence of classical mutational resistance mechanisms was confirmed and correlated with resistance 
phenotypes, results also showed a major role of unexpected mutations. Among them, PBP3 mutations, 
shaping up β-lactam resistance, were noteworthy. A high selective pressure for mexZ mutations was 
evidenced, but we showed for the first time that high-level aminoglycoside resistance in CF is likely 
driven by mutations in fusA1/fusA2, coding for elongation factor G. Altogether, our results provide 
valuable information for understanding the evolution of the mutational resistome of CF P. aeruginosa.
Pseudomonas aeruginosa chronic respiratory infection (CRI) is the main driver of morbidity and mortality in 
patients suffering from cystic fibrosis (CF). The CF respiratory tract is a dynamic, heterogeneous, hostile, stressful 
and very challenging scenario for invading bacteria, but P. aeruginosa populations can overcome all these chal-
lenges and chronically persist in the CF lungs. Mechanisms underlying early acquisition of P. aeruginosa infection 
and the eventual establishment of CRI are complex and, many factors, related to the patient, the environment and 
the microorganism, are involved1–3.
The high versatility and adaptability observed for P. aeruginosa can be attributed to its complex and large 
genome (5–7 Mb), which includes an outstanding intrinsic antibiotic resistance machinery and a large propor-
tion of regulatory genes (>8%). In comparison to other Gram-negative pathogens, P. aeruginosa exhibits a basal 
reduced susceptibility to many antibiotics, attributed to the production of an inducible AmpC cephalosporinase, 
the constitutive (MexAB-OprM) or inducible (MexXY) expression of efflux pumps, and the reduced permeability 
of its outer membrane. In addition, P. aeruginosa intrinsic resistance can be significantly enhanced by the acquisi-
tion of multiple mutations that alter the expression and/or function of diverse chromosomal genes4–6.
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Early infection by P. aeruginosa in CF patients can be intermittent and usually different strains with distinct 
antibiotic susceptibility profiles are involved. However, according to the US CF Foundation Patient Registry, 
over 70% of CF patients are chronically colonized with P. aeruginosa by the age of 25 (Annual Report 2015); 
moreover, in up to 20% of them the involved strain is multidrug resistant (MDR). Although no single mutation 
can lead to an MDR profile, during CF CRI, P. aeruginosa is exposed to numerous and extended antimicrobial 
therapies which act as selective forces driving to the acquisition of a plethora of adaptive mutations that even-
tually lead to an enhanced antimicrobial resistance pattern. Moreover, this genetic adaptation is accelerated by 
the characteristic high prevalence of hypermutable strains (30–60%)7–10. Additionally, there is growing evidence 
suggesting that adaptation to the CF lungs may escape from the scale of the individual patients. Indeed, another 
remarkable and challenging issue in the CF setting is the existence of concerning P. aeruginosa epidemic strains, 
such as the Liverpool Epidemic Strain (LES-1), the Denmark Epidemic Strain (DK2) or the Australian Epidemic 
Strains (AES-1, AES-2 and AES-3), as these successful strains are able of infecting hundreds of CF patients even 
in different geographical locations and, indeed, in many cases exhibiting a MDR profile11–13. Therefore, CF CRI by 
widespread strains may provide a unique and exceptional opportunity to get insight into long-term evolutionary 
dynamics of P. aeruginosa mutational resistome.
Recent advances in sequencing technologies have made it possible to obtain the whole genome of bacterial 
pathogens. As mentioned above, P. aeruginosa CF CRI represent a unique chance to perform evolutionary studies 
and, accordingly, several works have been performed in this setting; however, most have focused their attention in 
pathoadaptive mutations14. Moreover, P. aeruginosa chronic infections are not limited to CF patients, being also 
frequently implicated in other chronic underlying diseases such as bronchiectasis and chronic obstructive pulmo-
nary disease (COPD)15. Thus, an insight into the resistome evolution during CF CRI could be of great benefit not 
only for individual patients but also for developing new drugs and new treatment strategies.
In a previous study we detected the presence of a transmissible and persistent P. aeruginosa lineage chronically 
infecting up to 4 of 10 selected chronically infected CF patients attended at the reference hospital of the Balearic 
Islands, Spain16. These isolates belonged to the ST274 clonal complex (CC274), which according to the MLST 
database, appears to colonize CF patients worldwide (http://pubmlst.org/paeruginosa/). In this work, the whole 
genome of a collection of CC274 strains was obtained in order to characterize the phylogeny, and the mutational 
resistome evolution of this widespread clonal complex; the CC274 collection included 29 representative isolates 
recovered from different regions of two highly distant countries, Australia and Spain, covering an 18-year period 
(1995–2012) and including sequential isolates from several patients (Fig. 1).
Results and Discussion
Prevalence and genetic basis for hypermutation: CC274 mutome. Among the CC274 studied col-
lection, nine isolates (31%) were mutators, belonging to six (35%) different patients, residing in both Australia 
(n = 3) and Spain (n = 3). Data from sequential isolates were available for the Spanish isolates: one was chroni-
cally infected with a persistent mutator lineage (FQSE24), whereas the other two harbored a mixed population of 
mutator and non-mutator isolates (FQSE06 and FQSE15) (Fig. 1).
Figure 1. CC274 P. aeruginosa collection. Sampling time from the 29 studied isolates can be inferred from the 
X axis. Isolates are labelled according to the following format: Patient identification - Country (AUS: Australia; 
SPA: Spain), Region.
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In order to evaluate the genetic basis of hypermutation, complementation studies with plasmids harboring 
wild-type Mismatch Repair system (MMR) genes (mutS and mutL) were performed in mutator isolates from 
these six patients. As shown in Table 1, wild-type rifampicin resistance mutation frequencies were restored in 
all mutator isolates upon mutS or mutL complementation, which correlated in all cases with the presence of 
specific mutations in these genes, documented through whole-genome sequencing. The three Australian muta-
tor isolates showed unique mutations in either mutL and mutS. Interestingly, all mutator isolates from the three 
Spanish patients were found to share the same inactivating mutation in mutS. On the other hand, while mutator 
phenotypes could be explained in all cases by specific mutations in MMR genes, the contrary was not always 
true, since one of the non-mutator isolates showed a missense mutation in mutS. Moreover, the presence of poly-
morphisms in other mutator genes was frequent, but showed no association with mutator phenotypes (Table 1). 
Overall, the prevalence and genetic basis of hypermutation in CC274 was similar to that previously documented 
for non-clonal CF populations9, 10; this study is however, to our knowledge, the first investigating the genetic basis 
of hypermutation from whole genome sequence data, through the analysis of the sequence of an exhaustive panel 
of so called mutator genes, thus designated mutome.
Phylogeny and interpatient dissemination of the international CC274 CF clone. Pulsed Field Gel 
Electrophoresis (PFGE) macrorestriction patterns indicated that all isolates were clonally related, including muta-
tors, which were indistinguishable from non-mutators. When an UPGMA (Unweighted Pair Group Method with 
Arithmetic Mean) dendrogram was constructed based on PFGE patterns, all isolates from the Balearic Islands 
clustered together in the same branch, although patterns from one of the patients (FQSE10) were slightly differ-
ent. In contrast, Australian isolates were less clonal and clustered in different branches (Supplementary Fig. S1).
Conversely, by Multi Locus Sequence Typing (MLST), two new and closely ST274-related sequence types (ST) 
were detected. Discrepant MLST and PFGE results were linked, directly or indirectly, to the emergence of a muta-
tor phenotype, an event that has already been documented in the CF context16–18. Mutators from patients FQSE15 
and FQSE24 differed from ST274 by only two point mutations in two of the MLST alleles (acsA and guaA) leading 
Isolate IDa ST Mutator?
Complement 
with
Sequence variation in mutator genes (mutome)b
ung mfd mutS sodB mutT sodM mutL mutM oxyR polA
AUS034 274 Yes mutL E236D R631C D61N L132P D876E
AUS410 274 No — E25V D876E
AUS411 274 No — E236D D61N D876E
AUS531 274 No — E236D D61N D876E
AUS588 274 No — E25V D876E
AUS601 1043 Yes mutL S13R E25V P159S H288Y F106L H219Y D876E
AUS603 274 No — E25V D876E
AUS690 274 Yes mutS Q1123H C224R T287P E236D D61N D876E
FQRC10 274 No — E236D D61N D876E
FQRC15 274 No — E236D D61N D876E
FQRC26 274 No — E236D D61N D876E
FQSE03 274 No — L374V E236D D61N D876E
FQSE06-0403 274 No — E236D D61N D876E
FQSE06-1104 274 Yes mutS Nt814Δ4 E236D D61N D876E
FQSE06-0807 274 No — E236D D61N D876E
FQSE06-0610 274 No — E236D D61N D876E
FQSE10-0503 274 No — E236D D61N D876E
FQSE10-0106 274 No — E236D D61N D876E
FQSE10-0110 274 No — E236D D61N D876E
FQSE10-0111 274 No — E236D D61N D876E
FQSE15-0803 274 No — E236D D61N D876E
FQSE15-0906 274 No — E236D D61N D876E
FQSE15-0310 274 No — E236D D61N D876E
FQSE15-1110 1089 Yes mutS A868T Nt814Δ4 E236D D61N D876E
FQSE24-0304 1089 Yes mutS Nt814Δ4 E236D D61N D876E
FQSE24-1005 1089 Yes mutS Nt814Δ4 E236D D61N D876E
FQSE24-0308 1089 Yes mutS Nt814Δ4 E236D D61N D876E
FQSE24-1010 1089 Yes mutS Nt814Δ4 E236D D61N D876E
PAMB148 274 No — E236D L202R D61N D876E
Table 1. Mutator phenotype and genetic basis of hypermutation in CC274. aIsolates are labelled according to 
the following format: Patient identification - MMYY isolation code in the case of sequential isolates. bSequence 
variations respect to those of PAO1. No mutations were found in other genes associated with mutator 
phenotypes, including pfpI, mutY, dnaQ, PA2583, PA2819.1, PA2819.2, radA and uvrD.
www.nature.com/scientificreports/
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to ST1089, as previously described16. Nevertheless, the mutator from patient FQSE06, which indeed shared the 
same inactivating mutation in mutS, still belonged to ST274 (Table 1). On the other hand, the Australian mutator 
AUS601 was also determined to be a new ST (ST1043), but, in this case, a direct link of the observed PFGE-MLST 
discrepancy with its MMR system (MutL) deficiency was suggested, since this isolate showed two missense muta-
tions in mutL (Table 1), one of them (H288Y) responsible for the generation of the new ST.
To better understand the evolutionary trajectory, success and international dissemination of CC274, 
whole-genome based phylogenetic analysis of all 29 isolates were performed. Previous studies have already 
demonstrated that almost all P. aeruginosa strains cluster into two major phylogenetic groups, one including 
PAO1 and the other PA1419. In order to determine the genetic relationship between CC274 isolates and other 
well-recognized CF epidemic clones, whole-genome sequence reads of all 29 isolates were de novo assembled 
and a phylogenetic tree based on core genome alignment was constructed with default parameters on Parsnp20. 
CC274 was determined to belong to the phylogenetic cluster containing strain PAO1, as well as other well-known 
CF epidemic clones such as LESB58, AES-1 and DK2 (Fig. 2a).
By mapping sequence reads for each isolate against P. aeruginosa reference PAO1 strain genome, up to 16,070 
common SNPs were found, as well as a total of 5,525 high-quality intraclonal SNPs, of which 2,294 were unique 
and thus detected in single isolates. A high degree of intraclonal diversity was observed, with SNP differences 
between isolates ranging from 20 to 3,256. To elucidate the phylogenetic relationship among isolates two different 
approaches were used. In both, core-genome and Bayesian time-based analysis, CC274 isolates grouped into two 
clusters, one including just four Australian isolates and a second major cluster that included all other Australian 
and Spanish isolates (Fig. 2b and Fig. 3). SNP differences between isolates from the different clusters ranged from 
2396 to 3256 and, according to Bayesian time-based analysis, the common ancestor of CC274 was set, approxi-
mately, 380 years ago.
The major cluster further subdivided and, although both phylogenetic reconstructions did not match exactly 
with each other, both analyses supported that different lineages are currently coexisting with a worldwide dis-
tribution, having evolved from a common antecessor set approximately 275 years ago. SNP differences between 
isolates from Australia and Spain ranged from 114 to 1204, and similar results were obtained when only the 
Australian (min-max: 230–826) or the Spanish (min-max: 20–839) were compared, supporting no geographical 
barrier for lineage evolution.
Within the major cluster, all sequential isolates cultured from an individual patient clustered under the same 
branch with the single exception of all the Spanish isolates that exhibited a mutator phenotype which clustered 
together, independently of the patient involved and their ST. Along with the fact that all these mutators shared the 
same inactivating mutation in mutS, as well as many unique antibiotic resistance mutations (Supplementary Data 
Set S1), phylogenetic analysis clearly demonstrated that ST1089 mutators evolved from a mutator ST274 isolate 
and that transmission of mutators among the Spanish CF patients occurred at some time point.
Focusing on the sequential isolates, a unidirectional evolution route could not be stablished. Instead, a diver-
sified intrapatient clone evolution that leads to a mix of genetically different sublineages coexisting in the CF 
respiratory airways was observed. Within a patient, minimum and maximum SNPs differences between isolates 
ranged from 20 to 676, which overlapped with interpatient SNPs differences, ranging from 51 to 3256 (51 to 839 
for patients from the same hospital). Similar results have been reported recently by Williams et al. concerning the 
Figure 2. Core-genome phylogenetic reconstructions of P. aeruginosa CC274 CF clone. (a) Genetic 
relationship between CC274 and other well-recognized CF epidemic clones. (b) Genetic relationship between 
the CC274 collection isolates. Both reconstructions were made with Parsnp using default parameters. Isolates 
are labelled according to the following format: Patient identification - MMYY isolation code in the case of 
sequential isolates - Country (AUS: Australia; SPA: Spain) - Region. Mutator isolates are identified with an 
asterisk.
www.nature.com/scientificreports/
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Liverpool Epidemic Strain, finding that multiple coexisting LES lineages are typically infecting CF patients and 
that genetic divergence between lineages within patients was greater than interpatient diversity, implying acquisi-
tion of diverse genetic populations21. However, another study focusing on the LES isolated from patients residing 
the UK and Canada showed less genetic differences, even when transoceanic isolates were compared22. Likewise, 
Yang et al. documented a lower genetic divergence in the DK2 epidemic clone23. Moreover, previous studies with 
other relevant and/or persistent CF clones have also reported divergent results24–26. A possible explanation for 
all these observations could be that different routes for adaptation and survival in the CF lung environment are 
possible and depend on the specific clonal lineages.
CC274 resistome. Minimum inhibitory concentrations (MICs) determined for a panel of 11 antipseu-
domonal agents are shown in Table 2. Resistance rates were lowest for colistin (3.4%), distantly followed by 
ceftazidime and piperacillin-tazobactam (13.8%). In contrast, resistance to cefepime, aztreonam, imipenem, 
amikacin and ciprofloxacin was observed in 44.8 to 62% of the isolates. Remarkably, 17.2% of the isolates were 
resistant to the new combination ceftolozane-tazobactam. As shown, antibiotic resistance was more frequent 
among mutators, and in Australian isolates in comparison with those from Spain. In fact, all 9 mutator isolates 
were classified as MDR, as compared to only 3 of 20 non-mutators. Moreover, one of the Australian mutator iso-
lates met the pan-drug resistant (PDR) definition27.
The presence of horizontally acquired resistance determinants was explored in the whole-genome sequences 
using the ResFinder tool28. None of the 29 isolates harbored any horizontally acquired genes encoding resistance 
determinants, thus indicating that the observed antibiotic resistance profiles reflected the accumulation of muta-
tions within the chromosomal genes. The complete list of antibiotic resistance related genes investigated (n = 164) 
as well as all missense and non-sense mutations encountered for each of the isolates studied are reported in the 
Supplementary Data Set S1. Up to 127 (77.4%) of the 164 studied genes showed non-synonymous mutations in 
at least one of the isolates studied. Moreover, after discarding non-synonymous mutations present in all isolates 
(and thus considered intrinsic CC274 polymorphisms), this figure only decreased to 106 (64.6%). Figure 4 shows 
the number and distribution of mutations among the 164 antibiotic resistance related genes studied in the CC274 
collection. Seventy-three (68.9%) of these genes showed no more than two different mutational events being 44 of 
them mutated in unique isolates. In contrast, 33 (31.1%) genes appeared to be under high evolutionary pressure 
showing evidence of at least 3 different mutational events. Particularly noteworthy among them were mexB or 
mexY, (coding for efflux pumps proteins), mexZ (the main MexXY repressor), gyrA (which codes for DNA gyrase 
subunit A) and fusA1 (coding for the elongation factor G).
The main antibiotic resistance related mutations documented are listed in Table 2 along with the susceptibil-
ity profiles for each of the isolates. For this purpose, the full list of mutations in the 164 genes studied (available 
Figure 3. Bayesian phylogenetic reconstruction of P. aeruginosa CC274 CF clone. The tree was based on 5525 
intraclonal variable positions identified by whole-genome sequencing. Divergence times of predicted ancestors 
and sampling dates can be inferred from the X axis taking into account that time zero corresponds to the most 
recent isolate (2012). The same labelling of Fig. 2 was used. Isolates characteristics are summarized at the right 
board, where: (CF) Cystic Fibrosis CRI and (B) Bloodstream. Sequential P. aeruginosa isolated from a same 
patient are indicated with the same colour.
www.nature.com/scientificreports/
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Isolate IDa
Antibiotic resistance profile (MIC values)b Hyperexpression?
Main antibiotic resistance mutations encounteredc
TZ 
(≤8)
PM 
(≤8)
AT 
(≤1)
PPT 
(≤16)
C/T 
(≤4)
IP 
(≤4)
MP 
(≤2)
TO 
(≤4)
AK 
(≤8)
CI 
(≤0.5)
CO 
(≤2) AmpC MexAB MexXY
AUS034*  > 256  > 256  > 256  > 256 16  > 32  > 32 6  > 256 1.5  > 256 + − +
gyrB (R441L), mexR (R85H), mexA (M1*), mexB (F178S, 
M555I), oprD(E264*), phoQ(E266*), parR (M59I), 
mexY(V1000L), mexZ(Nt334Δ13), fusA2(P329L), 
PA2489(R12L, A244T), mexS (P254Q), mexT(L157M), 
PBP4(W350R), capD (I7M, S51G), gyrA(T83I), mexK 
(S426G), mpl (Nt112ins1, V124G), fusA1 (V93A, P554L, 
D588G), rpoB (D831G, D964G), mexW (A627V, Q771P), 
PBP3 (P527T, G63S)
AUS410 4 24 1 12 4  > 32  > 32 64  > 256 1 0.38 − − +
gyrB (S466F), mexB(M552T), oprD (Nt583Δ1), lasR 
(A50V, D73G), sucC (V44G, A384V), oprF (Nt574Δ31), 
mexY (V32A), mexZ (Q164*), mexT (D327Y), mexE 
(F7Y), mpl (D168Y), PA2489(A125T, G185S, P260S), 
capD(I7M, S51G), fusA1(P618L), rpoC(E386K), 
mexW(Q511R), PBP3(G216S), pagL(Nt286Δ1), 
amgS(S64L)
AUS411  > 256  > 256  > 256  > 256 6  > 32  > 32  > 256  > 256 0.38 0.25 − − +
gyrB (S466F), mexB (Q104E, F246C, L376V), phoQ 
(H248P), lasR (D73G), parS (D381E, T163N), sucC 
(C261G), mexY (D201A, G287A), PA2489 (R12L, 
A244T), fusA2 (I640L), mexE (V104G), htpX 
(Nt683Δ5), mexK (S426G), capD (I7M), fusA1 (K504E), 
rpoC (N690S), mexW (A627V,Q771P), PBP3 (Q372P), 
pagL (N159D)
AUS531 3 3 4 12 1 2 0.75 1 6 0.125 1 − − − PA2489 (R12L, A244T), capD (I7M, S51G), mexW (A627V, Q771P)
AUS588 2 8 3 8 1 1 0.75 1 8 0.125 0.75 − − − PA2489 (A125T, G185S, P260S), mexE (F7Y, V276M), capD (I7M), mexW (Q511R)
AUS601*  > 256  > 256  > 256 1 3  > 32  > 32 24  > 256 16 0.25 − − +
mexB (M552T), oprD (Nt1044ins4), phoQ (K234N, 
T315A), lasR (A50V), sucC (T102I, A384V), mexY 
(V32A), mexZ (Q164*), fusA2 (S445*), mexT(D327Y), 
mexE(F7Y), ftsK (A152V), PA2489 (A125T, G185S, 
P260S), capD (S51G), gyrA (T83I), mpl (G113D), fusA1 
(P618L), rpoC (E386K), mexW (Q511R), PBP3 (R504C), 
pagL (E163G), pmrB (L31P), amgR (E204D)
AUS603 6 8 24 2 1.5  > 32 8 1 8 0.25 1.5 + − +
mexB (M552T), lasR (A50V, D73G), sucC (V44G, 
A384V), mexY (V32A), mexZ (Q164*), mexT (D327Y), 
mexE (F7Y), PA2489 (A125T, G185S, P260S), PBP4 
(S315G), opmE (E204D), capD (I7M, Nt1438Δ1), mpl 
(Nt112ins1, Nt1317Δ1), fusA1 (P618L), mexW (Q511R)
AUS690* 6 12 0.75 3 6 4 2 24  > 256 12 0.125 − + +
gyrB (Q467R), mexR (H133P), mexB (Nt712Δ1), phoP 
(T221I), lasR (T178I), parS (L10P), oprF (K250R), mexY 
(G402S, A850T), mexZ (Nt529Δ1), PA2489 (R12L, 
A244T), fusA2 (L104P, Nt889Δ1), htpX (G187D), capD 
(I7M, S51G), gyrA (T83A, T325I), mexK (G487E), mexH 
(Nt1086ins1), fusA1 (Y552C, T671I), rpoC (E136G, 
D616G, V808L), rpoB (F1046S), mexW (A627V, Q771P), 
pagL (P158L), pmrB (F124L), amgS (R188C), parE 
(P438S)
FQRC10 2 2 4 12 1 1.5 1 1 8 0.094 0.5 − − − PA2489 (R12L, A244T), capD (I7M, S51G), mexH (D356N), mexW (A627V, Q771P)
FQRC15 1 0.75 6 6 1 1.5 1 0.75 8 0.19 1 − − − PA2489 (R12L, A244T), capD (I7M), mexW (A627V, Q771P)
FQRC26 4 6 24 24 1 0.25 1.5 1 6 1.5 0.38 − + −
mexY (V875M), mexT (R164H), PA2489 (R12L, A244T), 
capD (I7M, S51G), gyrA(Q106L), mexW (A627V, 
Q771P)
FQSE03 3 8 0.5 2 1.5 2 0.38 1 6 3 0.25 − − +
mexA (L338P), lasR (P117G), mexZ (A144V), PA2489 
(R12L, A244T), capD (I7M, S51G), gyrA (D87N), mexW 
(A627V, Q771P)
FQSE06-0403 0.75 2 0.25 4 0.38 1 0.5 24 16 0.19 0.19 − − +
mexA (L338P), lasR (P117G), mexY (G287A), mexZ 
(S9P), PA2489 (R12L, A244T), mpl (S257L), capD (I7M, 
S51G), fusA1 (Y552C, T671I), mexW (A627V, Q771P), 
PBP3 (P215L), amgR (A8V)
FQSE06-1104* 0.38 1 0.094 0.38 0.38 6 0.19 1 24 0.75 2 − − +
mexA (L338P), lasR (P117G), mexZ (A194P), PA2489 
(R12L, A244T), fusA2 (N236S, N561S), capD (I7M, 
S51G), gyrA (D87G), mexK (Q585*), rpoB (Y583C), 
mexW (A627V, Q771P), pmrB (V185I, G221D, R287Q), 
PBP1A (E161G), amgR (A8V)
FQSE06-0807 4 8 0.75 4 2 1.5 0.75 24 >256 0.5 1 − − +
mexA (L338P), lasR (P117G), mexY (G287A), mexZ 
(S9P), mexT (P270Q), PA2489 (R12L, A244T), mpl 
(S257L), capD (I7M, S51G), fusA1 (N482S, Y552C, 
T671I), mexW (A627V, Q771P), PBP3 (P215L), amgR 
(A8V)
FQSE06-0610 4 24 0.75 8 1.5 1 0.25 1.5 24 0.75 0.19 − − +
mexA (L338P), lasR (P117G), mexZ (Nt290Δ11), 
PA2489 (R12L, A244T), mexW (A627V, Q771P), capD 
(I7M, S51G), amgR (A8V)
FQSE10-0503 1.5 12 4 4 1.5 1 0.25 0.75 8 0.25 0.25 − − +
mexY (V875M, N1036S), mexZ (IS), PA2489 (R12L, 
A244T), ftsK (A38T), nalD (Nt459Δ13), mexW (A627V, 
Q771P), capD (I7M, S51G)
Continued
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Isolate IDa
Antibiotic resistance profile (MIC values)b Hyperexpression?
Main antibiotic resistance mutations encounteredc
TZ 
(≤8)
PM 
(≤8)
AT 
(≤1)
PPT 
(≤16)
C/T 
(≤4)
IP 
(≤4)
MP 
(≤2)
TO 
(≤4)
AK 
(≤8)
CI 
(≤0.5)
CO 
(≤2) AmpC MexAB MexXY
FQSE10-0106 0.75 3 0.125 0.75 0.5 0.38 0.032 0.75 4 0.38 1.5 − − +
mexB (L738P), mexY (V875M, N1036S), mexZ (IS), 
PA2489 (R12L, A244T), ftsK(A38T), capD (S51G), nalD 
(Nt396Δ2), mexW (A627V, Q771P), nfxB (*188ext)
FQSE10-0110 3 8 16 8 2 1 0.125 0.75 4 0.75 0.5 − + +
mexY (V875M, N1036S), mexZ (IS), PA2489 (R12L, 
A244T), ftsK (A38T), rpoB (D659E, E904K), mexW 
(A627V, Q771P), pmrB (R287Q)
FQSE10-0111 3 16 12 12 8 1.5 1 1 12 0.38 0.38 − − +
mexY (V875M, N1036S), mexZ (IS), PA2489 (R12L, 
A244T), ftsK (A38T, D54Y), capD (S51G), mexW 
(A627V, Q771P)
FQSE15-0803 2 12 0.38 4 1.5 6 1 1 12 0.19 0.25 − − +
mexA (L338P), lasR (P117G), mexZ (A144V), PA2489 
(R12L, A244T), capD (I7M, S51G), pmrB (E213D), 
mexW (A627V, Q771P), amgR (A8V)
FQSE15-0906 0.75 6 0.38 2 1 1 0.047 1.5 12 0.38 0.75 − − +
mexA (L338P), lasR (P117G), mexZ (A144V), mexS 
(Nt848Δ2), mexT (Nt534Δ17), PA2489 (R12L, A244T), 
capD (I7M, S51G), mexK (S426G), mexW (A627V, 
Q771P), amgR (A8V)
FQSE15-0310 1 4 1 1 1 12 0.19 1 8 0.38 0.25 − − +
mexA (L338P), lasR (P117G), mexZ (A144V), mexS 
(Nt848Δ2), mexT (Nt534Δ17), PA2489 (R12L, A244T), 
capD (I7M, S51G), mexK (P834S), mpl (Nt1266Δ1), 
rpoC (Nt1181Δ3), mexW (A627V, Q771P), amgR (A8V)
FQSE15-1110* 8 24 6 4 1 >32 >32 1 16 1 0.25 − − +
gyrB (S466F), mexA (N71S, D235G), mexB (L376V), 
oprD (V67*), lasR (P117G), mexY (Y355H), mexZ 
(A194P), galU (P123L), PA2050 (G90R, Q161R), PA2489 
(R12L, A244T), fusA2 (N236S, N561S), htpX (A141T), 
capD (I7M, S51G), fusA1 (K430E), rpoC (V693A), mexW 
(A627V, Q771P), pmrB (R287Q), PBP1A (E161G), amgS 
(D267N), amgR (A8V)
FQSE24-0304* 2 24 0.38 8 1 >32 >32 2 24 6 0.38 − − +
gyrB (S466F), mexA (L338P), oprD (V67*), lasR 
(P117G), mexY (Y355H), mexZ (A194P), galU (P123L), 
PA2050 (G90R, Q161R), PA2489 (R12L, A244T), fusA2 
(N236S, N561S), opmE (D421G), capD (I7M, S51G), 
fusA1 (K430E), rpoC (V693A), mexW (A627V, Q771P), 
pmrB (R287Q), PBP1A (E161G), amgR (A8V)
FQSE24-1005* 1 16 0.38 2 1.5 >32 8 3 16 6 1 − − +
gyrB (S466F), oprD (V67*), lasR (P117G), mexY 
(Y355H), mexZ (A194P), galU (P123L), PA2050 (G90R, 
Q161R), fusA2 (N236S, N561S), PA2489 (R12L, A244T), 
fusA1 (K430E), rpoC(V693A), mexW (A627V, Q771P), 
pmrB (R287Q), PBP1A (E161G, R407S), amgR (A8V)
FQSE24-0308* 1 8 0.25 0.75 1.5 >32 0.25 2 16 4 1 − − +
gyrB (S466F), oprD (V67*), lasR (P117G), mexY 
(Y355H), mexZ (A194P), galU (P123L), PA2050 (G90R, 
Q161R), fusA2 (N236S, N561S), PA2489 (R12L, A244T), 
capD (I7M, S51G), fusA1 (K430E), rpoC (V693A), mexW 
(A627V, Q771P), pmrB (R287Q), PBP1A (E161G), amgS 
(T92A), amgR(A8V)
FQSE24-1010* 1 8 1 1 1 >32 4 4 64 4 0.38 − − +
gyrB (S466F), mexA (L338P), oprD (V67*), lasR 
(P117G), mexY (Y355H), mexZ (A194P), galU (P123L), 
PA2050 (G90R, P97L, Q161R), PA2489 (R12L, A244T), 
fusA2 (N236S, N561S), opmE (L400P, D421G), mexH 
(V221I), capD (I7M, S51G, A165V), fusA1 (K430E), 
rpoC(V693A), mexW (A627V, Q771P), PBP3 (G216S), 
pmrB (R287Q), PBP1A (E161G), amgS (A13V), amgR 
(A8V)
PAMB148 >256 64 >256 >256 6 1.5 0.75 1.5 16 0.064 0.5 + − −
PA2489 (R12L, A244T), capD (I7M, S51G), mexY 
(V875M, N1036S), mexW (A627V, Q771P), ampD 
(P41L)
% I + R 13.8 44.8 48.3 13.8 17.2 44.8 27.6 24.1 62.1 48.3 3.4
Table 2. Antibiotic susceptibility profile and main antibiotic resistance related mutations detected among 
CC274 isolates. aIsolates are labelled according to the following format: Patient identification - MMYY isolation 
code in the case of sequential isolates. Mutators isolates are identified with and asterisk. bMinimal Inhibitory 
Concentration (MIC) values were determined by grading MIC testing for the following antimicrobial agents: 
ceftazidime (TZ); cefepime (PM); aztreonam (AT); piperacillin-tazobactam (PPT); cefotolozane-tazobactam 
(C/T); imipenem (IP); meropenem (MP); tobramycin (TO); amikacin (AK); ciprofloxacin (CI) and colistin 
(CO). Clinical breakpoints established by EUCAST v7.0 for each antibiotic are shown in brackets. cThe main 
antibiotic resistance related mutations documented for each isolate are shown. For this purpose, the full list 
of mutations in the 164 genes studied (available in Supplementary Data Set S1) was refined to include only 
those more likely to be involved in the resistance phenotypes, by including: (i) mutations with known effect 
on resistance according to published evidence (ii) mutations for which our experimental evidence crosslinks 
resistance phenotypes and genotypes (e.g. mutations in genes involved in AmpC, efflux or OprD regulation and 
β-lactam resistance phenotypes are crosslinked by integrating the analysis of the expression of ampC, efflux 
pumps genes and oprD and/or (ii) mutations in genes found to be under high evolutionary pressure (those with 
at least 3 different mutational events documented).
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in Supplementary Data Set S1) was refined to include only those more likely to be involved in the resistance 
phenotypes, by including: (i) mutations with known effect on resistance according to published evidence, (ii) 
mutations for which our experimental evidence crosslinks resistance phenotypes and genotypes (e.g. mutations 
in genes involved in AmpC, efflux or OprD regulation and β-lactam resistance phenotypes are crosslinked by 
integrating the analysis of the expression of ampC, efflux pumps genes and oprD) and/or (ii) mutations in genes 
found to be under high evolutionary pressure (those with at least 3 different mutational events documented). 
As shown in Table 2, overall, the number of mutations was much higher (unpaired T test p < 0.0001) in mutator 
(19.2 ± 3.1) than in non-mutator isolates (6.7 ± 3.1). This is consistent with the much higher antimicrobial resist-
ance of mutators, documented in this and previous works8, 29. However, some Australian (e.g. AUS410 or AUS411) 
non-mutator isolates also presented a high number of mutations, perhaps indicating that under a high antibiotic 
pressure in long-term CRI, MDR profiles may emerge even in the absence of mutator phenotypes. Unique muta-
tions detected in specific genes support phylogeny reconstructions (see above Fig. 2b and Fig. 3). Moreover, they 
can be very useful to track interpatient transmission, considering that specific mutations detected in multiple 
isolates, especially within professional antibiotic resistance genes such as gyrB, oprD, mexY, creC, mexZ or fusA2, 
are unlikely to have occurred independently in different environments. Moreover, the analysis of these mutations 
Figure 4. Distribution of mutations among the CC274 collection. Mutations encountered among the 164 
antibiotic resistance related genes are represented, synonymous and common non-synonymous mutations have 
been excluded.
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can help to understand the basis for the intrapatient diversification and coexistence of multiple lineages in the CF 
respiratory tract.
To gain insights into the effect on the antibiotic resistance profiles of mutations listed in Table 2, the median 
MIC of isolates harboring mutations or not in a specific gene were compared and results are summarized in 
Fig. 5. Overall, it should be noted that colistin MICs as well as the MICs for the antibiotic combinations 
piperacillin-tazobactam and ceftolozane-tazobactam were barely affected, whilst carbapenems, aminoglycosides 
and quinolones MICs are affected by the presence of mutations in many of the selected genes. Apparently, the 
presence of mutations in some genes such as capD (also known as wbpM), a gene coding for a protein implicated 
in O-antigen biosynthesis and previously related with aminoglycoside resistance, or ftsK, which codes for a cellu-
lar division protein, were not related with an increase in resistance for any antibiotic. Conversely, the presence of 
mutations in 22 of the genes was shown to produce at least a 2-fold MIC increase for at least 3 different classes of 
antibiotics. Renowned resistance genes, such as gyrA, gyrB, ampD, dacB (PBP4) or oprD, are within this list of 22 
genes but, particularly interesting is the presence of not so well-recognized antibiotic resistance related genes such 
as fusA1 and fusA2, both coding for elongation factor G, or rpoC, which codes the β-chain of a DNA-directed 
RNA polymerase. Mutations in genes coding for two-component regulatory systems, as PhoPQ or ParRS, also 
require a special mention as mutated isolates showed a strong impact in their MICs for many of the antibiotics 
tested.
The presence of unique mutations in certain well-known antibiotic resistance genes, such as dacB (PBP4) was 
observed to increase β-lactam resistance, but it should be noted that mutations within a specific gene did not 
always correlate or lead to the expected effect on antibiotic resistance (e.g. pmrB or phoP-phoQ mutated isolates 
Figure 5. MIC-fold change for each antibiotic tested between isolates mutated or not mutated in a specific 
gene. To evaluate the implication of the presence of mutations in the main genes possibly related with antibiotic 
resistance the median MIC for both groups were calculated and compared, results are expressed in MIC-fold 
change. PA2489, mexW, oprF, parE and nfxB were excluded since the number of mutated isolates were < 3. 
Some genes were grouped (e.g. ampD and dacB (PBP4) or nalD and mexR) according to their well-established 
effects on resistance (e.g. AmpC or MexAB-OprM overexpression, respectively).
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did not exhibit a higher colistin MIC). Likewise, several mutations (e.g. mexZ, gyrB or oprD) were associated to 
extended unexpected antibiotic resistance profiles, perhaps suggesting the co-selection of different resistance 
mutations during P. aeruginosa evolution in CF CRI. A detailed analysis of the mutational resistome for each class 
of antibiotics is provided below and in the Supplementary Data Set S1.
β-lactam resistome. Overproduction of the chromosomally encoded cephalosporinase AmpC is the 
primary pathway for developing resistance to the antipseudomonal β-lactams, and it is driven by the selec-
tion of mutations in peptidoglycan-recycling genes (ampD, dacB and ampR)30, 31. Just three isolates (AUS034, 
AUS603 and PAMB148) of the CC274 collection were demonstrated to overproduce AmpC (Table 2). By con-
trast, at the genomic level, almost all isolates (26/29) contained some variation within dacB which codes for the 
penicillin-binding protein PBP4 (Supplementary Data Set S1-Betalactams). Crosslinking phenotypic and gen-
otypic results through ampC expression data, suggested that most observed dacB allele variations were, in fact, 
ancestral polymorphisms not involved in antibiotic resistance. However, AmpC overproduction in the two CF 
isolates was explained by the presence of specific mutations in dacB (S315G or W350R) and by an ampD (P41L) 
mutation in the case of the bloodstream infection isolate PAMB148 (Table 2). Whilst ampC overexpression in iso-
lates AUS034 and PAMB148 correlated well with ceftazidime and piperacillin-tazobactam resistance, this was not 
the case for isolate AUS603 which was documented to be susceptible to these antibiotics. However, unexpected 
AUS603 β-lactam susceptibility could be explained by the presence of chromosomal mutations whose effects 
eventually compensate the expected increase in β-lactam resistance. Indeed, this isolate showed a non-sense 
mutation in OprM (Q93X), the outer membrane protein of the constitutive MexAB efflux pump, which is well 
known to play a major role in intrinsic β-lactam resistance.
In addition, P. aeruginosa may eventually develop β-lactam resistance by acquiring mutations within their 
macromolecular targets: the essential penicillin-binding proteins (PBPs). While some mutations without appar-
ent effect on resistance were detected in genes coding for PBP1 and PBP3a, the main mutational resistance target 
among PBPs was found to be PBP3, an essential high molecular class B PBP with transpeptidase activity, in 
agreement with recent data from CF patients32 and in vitro studies33. Indeed, we documented that PBP3 muta-
tions had often occurred (7/29 isolates) among the CC274 collection (Supplementary Data Set S1-Betalactams). 
Nevertheless, β-lactam resistance contribution of each derived ftsI (PBP3) allele, if any, depends on the specific 
point mutation encountered. Missense mutations within the PBP3 (R504C and Q372P) were apparently the cause 
of β-lactam resistance in isolates AUS601 and AUS411, since they do not hyperproduce AmpC. Although these 
mutations are not located in the PBP3 active site, both are very close to two loop regions (residues 332–338 
and 526–533) which play an important role in substrate recognition34. In fact, PBP3 mutations in residue 504 
(R504C, R504H) have been recently described in vitro33 and among isolates from widespread nosocomial P. 
aeruginosa clones35, 36. Likewise, the P527T mutation of AUS034 likely contributes, together with the overex-
pression of AmpC, to the very high-level β-lactam resistance of this isolate, including the new antipseudomonal 
combination ceftolozane-tazobactam. On the other hand, the P215L and G216S mutations were apparently not 
linked with phenotypic resistance, in agreement with the fact that residues 215 and 216 are not implicated in the 
formation and stabilization of the inactivating complex β-lactam-PBP334.
Obtained data also demonstrated that the constitutive efflux pump MexAB-OprM is under strong mutational 
pressure during CF CRI, frequently including inactivating mutations, which correlates with previous investiga-
tions that pointed out that this efflux pump is dispensable and, therefore, tends to be lost or inactivated in favor of 
MexXY-OprM hyperproduction in CF P. aeruginosa subpopulations37. Our data also support this hypothesis, as 
just 3 isolates showed mutations in regulators leading to MexAB-OprM overexpression, whereas up to 23 isolates 
hyperproduced the efflux-pump MexXY-OprM (Supplementary Data Set S1 -Betalactams). Moreover, many of 
the isolates showed some degree of hypersusceptibiltiy to aztreonam (substrate of MexAB-OprM) in favor of an 
increased MIC of cefepime (substrate of MexXY-OprM) (Supplementary Data Set S1- Betalactams).
Carbapenem resistome. Imipenem and meropenem resistance correlated in all but two isolates with the 
presence of non-sense mutations affecting the outer membrane protein OprD (Table 2, Supplementary Data 
Set S1-Carbapenems). High-level meropenem resistance was additionally associated with the presence of PBP3 
mutations, in agreement with recent in vitro studies showing the selection of PBP3 mutations upon meropenem 
exposure33. Remarkably, all ST1089 mutator isolates shared the same point mutation in oprD (V67X) as well as 
in galU (P123L), also related with carbapenem resistance, supporting interpatient transmission of this mutator 
lineage among CF patients attending the reference hospital of the Balearic Islands.
The expression of OprD is known to be modulated by mutations (mexS or mexT) leading to the overexpression 
of the efflux pump MexEF-OprN, and meropenem is a well-known substrate for the efflux pump MexAB-OprM. 
However, carbapenem resistant isolates AUS411 and AUS603 harboring a wild-type oprD allele did not over-
produce neither of these two efflux pumps. Thus, the observed phenotype could be related with the presence 
of specific mutations within the genes coding for PBP3 (ftsI) and PBP4 (dacB), hypothesis that is current being 
evaluated in our laboratory.
Aminoglycoside resistome. Intravenous antimicrobial combinations including an aminoglycoside plus 
a fluroroquinolone or a β-lactam antibiotic are frequently used to manage CF exacerbations. Moreover, in the 
last decade, tobramycin inhalation has become an important contributor to CF treatment as a means to control 
chronic infection as well as a first-line treatment for the eradication of early acquisition of P. aeruginosa and sev-
eral aminoglycoside-based inhaled formulations are currently available. Resistance to antipseudomonal amino-
glycosides is frequently attributed to the presence of acquired aminoglycoside-modifying enzymes, membrane 
impermeability or MexXY efflux pump overexpression38. Moreover, adaptive resistance, due to MexXY efflux 
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system overexpression, to this class of antibiotics has been well documented in the CF setting in response to 
sublethal concentrations39.
Among the CC274 collection, a high proportion of the isolates (23/29) were shown to overexpress MexXY 
and all but one were mutated in mexZ, which codes for the mayor MexXY expression regulator. In agreement 
with recent work, which pointed out that mutation of mexZ is part of a strongly selected evolutionary pathway40, 
several different mutational events were encountered within this regulator. Remarkably, the same point mutation 
was detected among different and independent isolates, probably indicating interpatient transmission events 
(Table 2, Supplementary Data Set S1-Aminoglycosides). The single MexXY-overproducing isolate showing no 
mutations in mexZ, presented a unique mutation in parS, a gene also involved in the modulation of MexXY 
expression. Nevertheless, as it has been largely observed in the CF clinical setting41, MexXY hyperproduction 
per se cannot explain aminoglycoside resistance in the majority of the isolates. In this sense, there is growing evi-
dence that high-level resistance is a stepwise process which arises by the accumulation of several non-enzymatic 
mechanisms and, moreover, novel genetic resistance determinants have been proposed42–44. To our knowledge, no 
published work has yet investigated the in vivo contribution to aminoglycoside resistance of these novel genetic 
determinants proposed, and many questions remain unresolved. Thus, our work reveals for the first time that 
all high-level resistant isolates hyperproduced MexXY, but also harbored additional mutations in some of these 
genes, especially highlighting the presence of mutations in both genes coding for elongation factor G, fusA1 and 
fusA2 (Supplementary Data Set S1 - Aminoglycosides). In fact, fusA1 and fusA2 have been recently demonstrated 
to be under high evolutionary pressure in the CF environment, which can be explained in terms of a wide amino-
glycoside use in this setting45.
Fluoroquinolone resistome. P. aeruginosa RND (Resistance-Nodulation-Division) efflux pumps 
MexAB-OprM, MexXY-OprM, MexCD-OprJ and MexEF-OprN are well-known to extrude fluoroquinolones. 
Nevertheless, our data suggest that the contribution of the overexpression of these efflux pumps to high-level 
resistance to fluoroquinolones is very limited, if any (Supplementary Data Set S1 -Fluoroquinoles). Concerning 
MexCD-OprJ overproduction, it has been shown that, although wild type P. aeruginosa strains generally do 
not express this efflux system46, hyperproducing mutants tend to emerge after both in vitro and in vivo fluoro-
quinolone exposure33. Moreover, there is some data suggesting that MexCD-OprJ hyperproduction could be an 
advantage in the CF environment47. Among the CC274 collection, however, just 1 isolate (FQSE10-0106), show-
ing aa ciprofloxacin MIC below the resistance breakpoint (MIC = 0.38 mg/L), was demonstrated to hyperproduce 
MexCD-OprJ due to a non-sense mutation in nfxB.
On the other hand, our data shows that high-level fluoroquinolone resistance was associated with the pres-
ence of missense mutations in gyrA, gyrB and/or parC quinolone resistance-determining regions (QRDRs). 
Specifically, up to 9 isolates were mutated in gyrB QRDR and all but two harbored the same mutation (S466F), 6 
showed mutations in gyrA QRDR (T83I, T83A, D87N, D87G and Q106L), and just one isolate was mutated in 
parE (P438S). Mutations in GyrA residues 83 and 87 are well-known to be relevant in the clinical setting and are 
frequently encountered in fluoroquinolone-resistant P. aeruginosa35, 36, being both residues situated on helix-4. 
Mutations in residue 106 are in the other hand very infrequent, with only one previous reference of its existence 
in 1 of 335 quinolone resistant P. aeruginosa clinical strains48.
Polymyxin resistome. Two component-regulatory systems as well as other genes implicated in lipopoly-
saccharide biosynthesis have been related with polymyxin resistance49–51. Several in vitro works have addressed 
the implication of the two-component regulatory systems in polymyxin resistance development, demonstrating 
that individual alterations in these systems are generally not sufficient to develop high-level resistance50, 52–54 and 
that individual two-component systems may not be essential for acquisition of colistin (polymyxin E) resist-
ance in P. aeruginosa55. In agreement with these in vitro studies, we found that many isolates were mutated in 
genes such as pagL, phoQ or pmrB, but with one exception (i.e. isolate AUS034) phenotypic resistance was not 
observed (Table 2, Supplementary Data Set S1-Polymyxins). For isolate AUS034, a specific non-sense mutation 
was detected in the two-component sensor PhoQ, as well as two other specific point mutations within parR and 
colS. Five additional isolates were shown to harbour mutations in more than one polymyxin-resistance related 
genes and showing colistin MICs from 0.125 to 2 mg/L (Supplementary Data Set S1- Polymyxins). Remarkably, 
none of the mutations detected in the two-component regulatory systems PmrAB and PhoPQ have been previ-
ously described in the clinical setting, reflecting an individual strain adaptation to the CF lung36, 52, 53, 56. Six differ-
ent and independent mutational events were registered in PmrB sensor, being all but two located near the active 
site (H249). Moreover, Spanish mutators shared the same mutation, again reflecting the interpatient transmission 
of a CF-adapted mutator lineage.
Considering that colistin is widely used for the management of CF patients, the frequent documentation of 
mutations in genes such as phoQ, pmrB or pagL suggests a role in polymyxin resistance, tolerance or adaptation 
in vivo, even when phenotypic resistance is not demonstrated in vitro. Thus, further in vivo and clinical studies 
should be performed to decipher the impact of these mutations for the therapeutic management of CF patients.
Concluding remarks. Emergence of international epidemic CF clonal lineages, along with the extraordinary 
capacity of P. aeruginosa to develop resistance to all antibiotic classes, catalyzed by frequent mutator phenotypes, 
severely compromises the clinical management of P. aeruginosa CF CRI. In addition to the assessment of the 
emerge of mutator phenotypes within an international CF clone, we analyzed for the first time the genetic basis of 
hypermutation from whole genome sequence data, through the analysis of the sequence of an exhaustive panel of 
so called mutator genes, thus designated mutome.
CC274 population structure analysis demonstrated the coexistence of two separated and divergent clonal 
lineages, but without evident geographical barrier. Coexistence of distinct evolved sublineages within a patient 
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was documented, reflecting coexistence of divergent lineages within the infecting inoculum or alternatively, and 
less probable, multiple interpatient transmission events. More revealing is the confirmation, by both phyloge-
netic reconstructions and mutational resistome analysis, of interpatient transmission of mutators. Compared 
with classical molecular typing tools, WGS provides detailed genome fingerprints that might be essential for 
epidemiological studies in which prevalent and ubiquitous clonal lineages are involved. Indeed, WGS closely clus-
tered isolates from four of the patients from the Balearic Islands, likely indicating interpatient transmission or a 
common source of colonization, whereas isolates from a fifth patient from the same hospital was distantly related.
We have documented at whole genome level the extraordinary capacity of P. aeruginosa to acquire resistance 
by mutational events, evidencing the emergence of mutations in over 100 genes related to antibiotic resistance 
during the evolution of a CF epidemic clone. Moreover, our results confirm that the evolution of P. aeruginosa 
resistome is greatly enhanced when mutator phenotypes are selected. However, the difficulty for correlating geno-
typic with phenotypic variation (due to random drift mutations among other causes) has been a hallmark of WGS 
approaches. To minimize this limitation, the full list of mutations in the 164 genes studied was refined to include 
only those more likely to be involved in the resistance phenotypes. While the presence of classical mutational 
mechanisms, such as the overexpression of the β-lactamase AmpC, the inactivation of the carbapenem porin 
OprD, or QRDR mutations, was confirmed in a number of isolates and correlated with the resistance phenotypes, 
our results also provided evidence for the existence and important role of less expected resistance mutations and 
their phenotypes. Among them, PBP3 mutations, shaping up β-lactam resistance are particularly noteworthy. 
Likewise, our work, as previously others, denote the very high selective pressure for mexZ mutations, leading to 
the overexpression of MexXY, associated with aminoglycoside resistance. However, we show for the first time that 
high-level aminoglycoside resistance in CF is driven by the acquisition of additional mutations, particularly those 
in fusA1 or fusA2, coding for elongation factor G. Finally, a complex repertoire of mutations in genes related to 
polymyxin resistance is evidenced, but with limited correlation with in vitro phenotypic resistance. Altogether, 
our results provide valuable information for understanding the evolution and dynamics of the mutational resi-
stome of P. aeruginosa CF clones and it is correlation with resistance phenotypes, which might be useful for 
guiding new diagnostic tools and therapeutic strategies in CRI.
Material and Methods
P. aeruginosa CC274 collection and susceptibility testing. The CC274 collection included 29 iso-
lates: 28 recovered from 18 CF patients from Australia and Spain and 1 blood culture isolate from a Spanish 
non-CF patient, covering up to an 18-year period from 1995 to 2012. All isolates had been previously classified 
within the CC274 (sharing at least 5 alleles with ST274) based on MLST using available protocols and databases 
(http://pubmlst.org/paeruginosa/). All the Australian and 4 CF Spanish isolates were single isolates recovered 
from patients attending clinical settings located in different geographical areas, being each area represented by 
at least 2 independent isolates, selected randomly from those available. In addition, we included 4 sequential P. 
aeruginosa, each separated by at least 6-month intervals, from each of 4 CF patients attended at the reference hos-
pital of the Balearic Islands (Son Espases Hospital, Spain)(Fig. 1), thus representing intrapatient clone evolution. 
These patients were shown to be chronically colonized with this persistent strain in a previous study16. P. aerugi-
nosa PAO1 strain was used as reference when needed. Minimal inhibitory concentrations (MICs) of ceftazidime, 
cefepime, aztreonam, piperacillin-tazobactam, ceftolozane-tazobactam, imipenem, meropenem, tobramycin, 
amikacin, ciprofloxacin and colistin were determined by Etest and classified according EUCAST clinical break-
points (http://www.eucast.org/).
Molecular typing. Clonal relatedness among isolates was evaluated by PFGE. For this purpose, bacterial 
DNA embedded in agarose plugs prepared as described previously was digested with SpeI. DNA separation was 
then performed in a contour-clamped homogeneous-electric-field DRIII apparatus (Bio-Rad, La Jolla, CA) under 
the following conditions: 6 V/cm2 for 26 h with pulse times of 5 to 40 s. DNA macrorestriction patterns were ana-
lyzed with UPGMA to infer clonal relatedness (CLIQS 1D Pro, Totallab).
Mutant frequencies and genetic basis of hypermutation. Rifampicin (300 mg/L) resistance mutant 
frequencies were determined in all strains following previously established procedures9, 10. To explore the genetic 
basis for the mutator phenotypes, complementation studies were performed as described previously9. Briefly, 
plasmid pUCPMS harbouring PAO1 wild-type mutS, plasmid pUCPML harbouring PAO1 wild-type mutL, and 
plasmid pUCP24, a control cloning vector, were electroporated into the mutator isolates. Complementation was 
demonstrated by reversion of the increased rifampicin resistance mutant frequencies in two independent trans-
formant colonies for each strain. Additionally, the genetic basis of hypermutation was investigated from whole 
genome sequence data, through the analysis of an exhaustive panel of so called mutator genes, thus designated 
mutome. Genes included within the mutome panel, selected according to available informatio8 were the fol-
lowing: PA0355/pfpI, PA0357/mutY, PA0750/ung, PA1816/dnaQ, PA3002/mfd, PA3620/mutS, PA4366/sodB, 
PA4400/mutT, PA4468/sodM, PA4609/radA, PA4946/mutL, PA5147/mutM, PA5344/oxyR, PA5443/uvrD and 
PA5493/polA.
Characterization of resistance mechanisms. The levels of expression of ampC, mexB, mexD, mexY, 
and mexF were determined by real-time reverse transcription (RT)-PCR according to previously described pro-
tocols57. Additionally, for selected isolates, the sequences of resistance genes, such as oprD or mexZ was obtained 
by Sanger sequencing in order to confirm whole-genome sequencing data as needed. Briefly, after duplicate PCR 
amplification, sequencing reactions were performed with the BigDye Terminator kit (PE Applied Biosystems, 
Foster City, CA), and sequences were analyzed on an ABI Prism 3100 DNA sequencer (PE Applied Biosystems). 
The resulting sequences were then compared with that yielded by WGS technology.
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Library preparation and whole-genome sequencing. Genomic DNA was obtained by using a 
commercially available extraction kit (High Pure PCR template preparation kit; Roche Diagnostics). Indexed 
paired-end libraries were prepared with Nextera XT DNA library preparation kit (Illumina Inc, USA) and 
sequenced on an Illumina MiSeq® benchtop sequencer with MiSeq reagent kit v2 (Illumina Inc., USA), resulting 
in 250 bp paired-end reads.
Variant calling. Previously defined and validated protocols were used with slight modifications25, 58. 
Briefly, paired-ended reads were aligned to the P. aeruginosa PAO1 reference genome (GenBank accession: 
NC_002516.2) with Bowtie 2 v2.2.4 (http://bowtie-bio.sourceforge.net/bowtie2/index.shtml)59 and, eventually, 
pileup and raw files were obtained by using SAMtools v0.1.16 (https://sourceforge.net/projects/samtools/files/
samtools/)60 and PicardTools v1.140 (https://github.com/broadinstitute/picard). The Genome Analysis Toolkit 
(GATK) v3.4-46 (https://www.broadinstitute.org/gatk/) was used for realignment around InDels61. Median PAO1 
coverage was 95.75% (range: 90.4–97.6%). SNPs were extracted from the raw files if they met the following cri-
teria: a quality score (Phred-scaled probability of the samples reads being homozygous reference) of at least 50, 
a root-mean-square (RMS) mapping quality of at least 25 and a coverage depth of at least 3 reads; excluding all 
ambiguous variants. MicroInDels were extracted from the totalpileup files applying the following criteria: a qual-
ity score of at least 500, an RMS mapping quality of at least 25 and support from at least one-fifth of the covering 
reads. Finally, all positions in which at least one of the isolates showed some variation were manually and individ-
ually checked in all other isolates without applying any filtering.
De novo assembly. Sequence reads from each isolate were de novo assembled using Velvet v1.2.10 (https://
www.ebi.ac.uk/~zerbino/velvet/)62 with a k-mer length of 31 and the following parameters: scaffolding = no, 
ins_length = 500, cov_cutoff = 3, and min_contig_lgth = 500. The median size of the de novo assembled obtained 
genomes was 6.1Mbp, ranging from 5.4 to 6.6Mbp. MUMmer3 v3.2363 was used to align the obtained genomes 
against each other in order to confirm that all belong to the same clone type (genomes differing < 10,000 SNPs).
Phylogenetic reconstructions and BEAST analysis. Core genome phylogenetic reconstructions were 
performed using Parsnp from the Harvest Suite package v1.2 with default parameters forcing the inclusion of 
all genomes and a randomly selected reference genome (flags: -c / -r!) (http://harvest.readthedocs.io/en/latest/
content/parsnp.html)20. Bayesian analysis of divergence times was performed using BEAST v2.4.2 (http://beast2.
org/)64. For this purpose, a nexus file including all the curated positions at which at least one of the isolates 
differed from the reference strain PAO1 was constructed and converted into an.xml file with BEAUTi. BEAST 
was run with the following user-determined settings; a lognormal relaxed molecular clock model and a general 
time-reversible substitution model with gamma correction25. Divergence times were calculated from a chain 
length of 50 million steps, sampled every 1,000 steps and discarding the first 5 million steps as a burn-in. The 
maximum clade credibility tree was generated using the TreeAnnotator program from the BEAST package and 
tree parameters were calculated with Tracer v1.6 (http://beast.bio.ed.ac.uk/Tracer). Both Phylogenetic recon-
structions were displayed using FigTree v1.4.2 (http://tree.bio.ed.ac.uk/software/figtree/).
Profiling of antibiotic resistance genes. SNPs and InDels for each isolate were annotated by using 
SnpEff software v4.2 (http://snpeff.sourceforge.net/index.html)65 with default options. These files were then fil-
tered based on an exhaustive literature review35 that led us to obtain a set of 164 genes known to be related to 
chromosomal antibiotic resistance in P. aeruginosa (Supplementary Data Set S1). Additionally, we used the online 
tool ResFinder v2.1 (https://cge.cbs.dtu.dk//services/ResFinder/)28 to identify possible horizontally acquired anti-
microbial resistance genes.
Ethics statement. The study has been approved by the Research Committee from Son Espases University 
Hospital. All methods were performed in accordance with the relevant guidelines and regulations. Used isolates 
derived from frozen stocks of laboratory collections obtained from routine cultures. Patient’s information or 
tissue samples were not used in this study.
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